Clinical Trial Search

Primary: the Number of Participants With Glasgow Coma Score (GCS) < 14 Within the First 24 Hours of Treatment for Diabetic Ketoacidosis (DKA) — 10; 11; 11; 16 Participants — p=0.34

Primary: Change From Baseline to Week 24 in Maximum Cystometric Capacity (MCC) — 37.0 mL — p=<0.001

Primary: Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Acute Phase — 186; 186 Participants

Primary: Mean Weekly Hemoglobin Level From Week 30 to Week 34: Maintenance Period — 10.17; 10.11 g/dL

Primary: Percentage of Participants Achieving Seroresponse for Meningiococcal Group C Serotype — 100; 100 Percentage of participants

Primary: Improved Overactive Bladder Symptoms as a Measure of Efficacy of Mirabegron — 13; 14; 25; 6 Participants

Primary: Percentage of Patients With Adverse Events — 169; 174; 86; 90 Participants

Primary: Bronchodilation — 1.18; 2.72; 1.22; 2.90 liters — p=>0.05

Primary: Percentage of Patients With a Drug-related Adverse Event That is Recorded as Grade 3 or 4 or as a Serious Adverse Event (SAE) — 53.1; 53.1; 29.1; 27.3 percentage of…

Primary: Percentage of Participants Achieving an SLE Responder Index Response at Week 52 — 38.5; 34.8; 27.7 percentage of participants

Primary: ≥20% Reduction in Lesion Size at 48 to 72 Hours Compared to Baseline in All Randomized Patients. — 80.9; 81.0 percentage of participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 53; 13; 1; 0 Participants

Primary: Percentage of Subjects With Human Serum Bactericidal Activity (hSBA) Titer ≥ 1:5 Against Neisseria Meningitidis Serogroup B Strains — 0; 0; 100; 0 Percentages of subjects

Primary: Number of Patients With Ventricular Tachycardia (VT) or Ventricular Fibrillation (VF) or Death — 174; 198 Participants — p=0.117

Primary: Percentage of Participants With Primary Major Adverse Cardiovascular Events (MACE) Composite (75% Interim Analysis) — 8.0; 8.0 percentage of participants